Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Agents fibrinolytiques --- Antithrombotic agents --- Antithrombotics --- Fibrinolytic agents --- Fibrinolytic enzymes --- Fibrinolytics --- Fibrinolytische agentia --- Thrombolytic agents --- Thrombolytics --- Drugs --- Testing --- Moral and ethical aspects --- Prices --- Drugs - Testing - Moral and ethical aspects. --- Drugs - Prices - Moral and ethical aspects.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book is an essential, comprehensive text onglobal drug pricing and covers a range of pharmaceutical pricing issues. It has twenty-two chapters in total;nineteenof which are case studieson an array of high, middle, and low income countries. The final three chaptersdiscussvalue-based pricing, innovation, prices and the pharmaceutical industry and the link betweenpharmaceutical policy and pricing. As the pharmaceutical market continues to expand, a number of pharmaceutical pricing strategies have been employed to control drug expenditures. The book explores this phenomenon further and willserve a valuable resource for policy makers, funders, social insurance institutions and drug companies.  About the author Zaheer-Ud-Din Babar, PhD is the Head of Pharmacy Practice at the School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. A pharmacist by training and a PhD in pharmaceutical policy, Dr Babar is a recipient of the prestigious “Research Excellence Award” from the University of Auckland. His research program covers areas related to pharmaceutical policy and practice, encompassing access to and affordability of medicines, issues related to medicine pricing and pharmacoeconomics. Dr Babar has delivered invited lectures at Boston University School of Public Health, Harvard Medical School, the Austrian Health Institute and the Universities of Reading and Kingston. He has also acted as a consultant for the World Health Organization, Health Action International, the International Union against Tuberculosis and Lung Disease, the International Pharmaceutical Federation (FIP) and the Pharmaceutical Management Agency of New Zealand in the area of medicines pricing and policies. Dr Babar is the Editor in Chief of the Journal of Pharmaceutical Policy and Practice, www.joppp.org and can be reached at z.babar@auckland.ac.nz.

Economics/Management Science. --- Health Economics. --- Economics. --- Economie politique --- Drugs -- Prices. --- Pharmaceutical industry -- Political aspects. --- Pharmaceutical industry. --- Prescription pricing. --- Price regulation. --- Public Health --- Health & Biological Sciences --- Medical Economics --- Drugs --- Pharmaceutical policy. --- Prices. --- Marketing. --- Drug policy --- Drugs and state --- Pharmacy --- Pharmacy and state --- State and drugs --- State and pharmacy --- Government policy --- Health economics. --- Medical economics. --- Medical policy --- Economics, Medical --- Health --- Health economics --- Hygiene --- Medical care --- Medicine --- Economic aspects --- Farmaceutische producten : Farmaceutische specialiteiten --- Produits pharmaceutiques : Spécialités pharmaceutiques

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pharmacotechnology. Preparations --- Gray market --- Industrial property --- Restraint of trade --- Industrie pharmaceutique --- Marché gris --- Propriété industrielle --- Concurrence déloyale --- Marché gris --- Propriété industrielle --- Concurrence déloyale --- Drugs --- Pharmaceutical policy --- Pharmaceutical industry --- Competition, Unfair --- Médicaments --- Concurrence --- Law and legislation --- Droit --- Politique gouvernementale --- Restrictions --- Economic law --- Administrative law --- European Union --- Prices --- Grey market --- Parallel importation --- Markets --- Marketing channels --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Pharmacology --- Pharmacy --- Drugs - Prices - Law and legislation - European Union countries --- Gray market - Law and legislation - European Union countries --- Médicaments --- Europe de l'Ouest --- Libre-échange --- Propriété industrielle (droit européen) --- Intégration économique

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pharmaceutical industry --- Drugs --- Prescription pricing --- Advertising --- Pharmaceutical policy --- Costs --- Prices --- Research --- Finance --- 661.12 --- 343.53 --- Pharmaceutical products --- Commerciele fraude. Industriele fraude. Ongeoorloofde concurrentie --- Finance. --- Costs. --- 343.53 Commerciele fraude. Industriele fraude. Ongeoorloofde concurrentie --- 661.12 Pharmaceutical products --- Drug industry --- Drug trade --- Medicine industry --- Medicines industry --- Prescription medicine industry --- Chemical industry --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Pharmacology --- Pharmacy --- Ads --- Advertisements --- Advertising, Consumer --- Advertising, Retail --- Advertising, Store --- Commercial speech --- Consumer advertising --- Retail advertising --- Speech, Commercial --- Store advertising --- Business --- Communication in marketing --- Industrial publicity --- Retail trade --- Advertisers --- Branding (Marketing) --- Propaganda --- Public relations --- Publicity --- Sales promotion --- Selling --- Research&delete& --- 615.2 --- 615.1.01 --- geneesmiddelen (zie ook 615.035, 615.35) --- farmaceutische industrie --- Pharmaceutical industry - United States - Costs --- Drugs - Prices - United States --- Drugs - Research - United States - Finance --- Prescription pricing - United States --- Advertising - Drugs - United States --- Pharmaceutical policy - United States